Results 21 to 30 of about 53,202 (260)

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD. [PDF]

Kidney Int Rep
Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of 2 clinical trials.
Singh AK, Anker SD, Pitt B, Rossing P, Ruilope LM, Ahlers C, Farag YMK, Lambelet M, Brinker MD, Rohwedder K, Filippatos G, FIDELIO-DKD and FIGARO-DKD Investigators.   +11 more
europepmc   +5 more sources

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Cardiovascular Diabetology, 2020
Background Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice.
Chun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou, Shihchen Kuo   +3 more
doaj   +1 more source

GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease

, 2022
Objectives: We assessed the effect of GLP-1RAs on ischemic stroke prevention in the Asian population with type 2 diabetes (T2D) without established cardiovascular disease.
Chia-Hung Kao (173343), Chien-Ning Huang (1739806), Chung Y. Hsu (7255547), Hsin-Hung Chen (789932), Kai-Chieh Hu (10512205), Yi-Sun Yang (1739800)   +5 more
core   +1 more source

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs

Cardiovascular Diabetology, 2022
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2
Dario Giugliano, Miriam Longo, Simona Signoriello, Maria Ida Maiorino, Bruno Solerte, Paolo Chiodini, Katherine Esposito   +6 more
doaj   +1 more source

GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching. [PDF]

Liver Int
Choi J, Kamath T, Nguyen VH, Przybyszewski E, Song J, Carroll A, Michta M, Almazan E, Simon TG, Chung RT.   +9 more
europepmc   +2 more sources

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China

Frontiers in Endocrinology, 2022
BackgroundsRobust evidence have demonstrated the beneficial effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in T2D patients with cardiovascular diseases and chronic kidney disease ...
Cao Li, Shanshan Guo, Jiping Huo, Yiming Gao, Yiming Gao, Yilong Yan, Yilong Yan, Zhigang Zhao   +7 more
doaj   +1 more source

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

Military Medical Research, 2022
Abstract Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food
Michael Razavi, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong   +3 more
openaire   +3 more sources

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway

Journal of Diabetes Research, 2022
Background. GLP-1 receptor agonists (GLP-1RA) are common clinical agents that are clinically protective against diabetic complications, such as diabetic retinopathy (DR).
Liufeng Wei, Weiwei Mo, Shanshan Lan, Haiyan Yang, Zhenxing Huang, Xinghuan Liang, Li Li, Jing Xian, Xuemei Xie, Yingfen Qin, Faquan Lin, Zuojie Luo   +11 more
doaj   +1 more source

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysisResearch in context

EClinicalMedicine, 2023
Summary: Background: Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA plus sodium glucose cotransporter-2 inhibitors [SGLT-2i] combinations ...
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, Angelo Cignarelli, Suetonia Cressida Palmer, Patrizia Natale, Giovanni F.M. Strippoli, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino   +10 more
doaj   +1 more source

Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol. [PDF]

Obes Sci Pract
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are dominating the type 2 diabetes and obesity intervention landscape, yet their real‐world use is increasingly difficult to characterize amid widespread availability of non–FDA‐approved, compounded products obtained outside traditional healthcare systems.
Katz JM, Gearhardt AN, Griauzde DH.
europepmc   +2 more sources